Noninvasive Differentiation of Simple Steatosis and Steatohepatitis by Using Gadoxetic Acid–enhanced MR Imaging in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study
Authors:
- Diana FeierDFDiana Feier
- Andreas WibmerAWAndreas Wibmer
- Stefan TraussniggSTStefan Traussnigg
- Csilla BalassyCBCsilla Balassy
- Dietmar TamandlDTDietmar Tamandl
- Henrik EinspielerHEHenrik Einspieler
- Friedrich WrbaFWFriedrich Wrba
- Michael TraunerMTMichael Trauner
- Christian HeroldCHChristian Herold
- Ahmed Ba-SsalamahABAhmed Ba-Ssalamah
- 1 June 2014
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 271 (3) , 739-747
Abstract
To determine whether gadoxetic acid-enhanced magnetic resonance (MR) imaging can be used to distinguish between simple steatosis and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD), defined according to the steatosis activity and fibrosis (SAF) scoring system, which is based on the semiquantitative scoring of steatosis activity and liver fibrosis. The local institutional review committee approved this study and waived written informed consent. This was a retrospective study of gadoxetic acid-enhanced 3-T MR imaging performed in 81 patients with NAFLD (45 men [56%]; mean age, 56 years; range, 25-78 years). The MR images were analyzed by using the relative enhancement (the ratio of signal intensities of the liver parenchyma before and 20 minutes after intravenous administration of gadoxetic acid). Univariate and multiple regression analyses were applied to identify variables associated with relative enhancement measurements. The ability of relative enhancement to allow differentiation between simple steatosis and NASH was assessed by using area under the receiver operating characteristic (ROC) curve analysis. Relative enhancement negatively correlated with the degree of lobular inflammation (r = -0.59, P < .0001), ballooning (r = -0.44, P < .0001), and fibrosis (r = -0.59, P ≤ .0001), but not with steatosis (r = -0.16, P = .15). Patients with NASH had a significantly lower relative liver enhancement (0.82 ± 0.22) than those with simple steatosis (1.39 ± 0.52) (P < .001). Relative enhancement measurements performed well in the differentiation between simple steatosis and NASH, with an area under the ROC curve of 0.85 (95% confidence interval: 0.75, 0.91) (cutoff = 1.24, sensitivity = 97%, specificity = 63%). Gadoxetic acid relative enhancement was significantly lower in patients with NASH than in patients with simple steatosis, but further prospective studies are warranted.Keywords
This publication has 35 references indexed in Scilit:
- From NAFLD in clinical practice to answers from guidelinesJournal of Hepatology, 2013
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §ΔHepatology, 2010
- Nonalcoholic Fatty Liver Disease: A Review and UpdateDigestive Diseases and Sciences, 2010
- Nonalcoholic Fatty Liver DiseaseAmerican Journal of Roentgenology, 2008
- Nonalcoholic Fatty Liver DiseaseAnnals of Epidemiology, 2007
- Technology evaluation: A critical step in the clinical utilization of novel diagnostic tests for liver fibrosisJournal of Hepatology, 2007
- Non‐invasive markers to predict the liver fibrosis in non‐alcoholic fatty liver diseaseLiver International, 2006
- Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?Journal of Clinical Pathology, 2002
- Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2002
- Nonalcoholic steatohepatitisGastroenterology, 2001